|
 |
 |
|
ViziLite® Plus oral lesion
identification and marking system
The newest tool in the fight against
oral disease is the ViziLite® Plus oral lesion identification
and marking system.
ViziLite® Plus, from Zila Pharmaceuticals, combines the oral
screening technology of ViziLite, an advanced chemiluminescent light
technology to help detect oral abnormalities, with TBlue630™. TBlue630
is the only patented pharmaceutical-grade form of toluidine blue that
has been cleared by the FDA for use in marking lesions identified during
a ViziLite examination.
ViziLite Plus makes oral screening more comprehensive than ever before
and is indicated for use in individuals at increased risk of oral
cancer. If ViziLite reveals an abnormality, TBlue630 can be used to mark
suspicious lesions for further evaluation.
If you have questions regarding oral screening and your dental
health, please call our office at
503 665-6166.
www.vizilite.com
|
